Drug Trial Radar · NCT06671938
Safety, Tolerability, and Pharmacokinetics of Exidavnemab in Patients With Parkinson's Disease and Patients With Multiple System Atrophy
Last checked: Nov 19, 2026Latest source record: Aug 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
38
Actual
Start
Oct 24, 2024
Primary completion
Aug 10, 2026
Study completion Aug 10, 2026
Sponsor
- Lead sponsor
- BioArctic ABIndustry
- Sponsor type
- Industry
- Collaborators
- Worldwide Clinical Trials
- First posted
- Nov 4, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to assess the safety and tolerability of exidavnemab after multiple dosing versus placebo.
Conditions
- Parkinson Disease
- Multiple System Atrophy
Interventions
exidavnemabDrug
The trial medication will be administered as an intravenous (IV) infusion (dose 1; dose 2)
Placebo ComparatorDrug
The trial medication will be administered as an intravenous (IV) infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with adverse events (AEs) and serious adverse events (SAEs).Time frame: From first dose to Day 176
Locations
7 sites in 2 countries. Site status is shown where the registry gives one.
Centrum Medyczyne Neuromed Sp. z o.o.
Bydgoszcz, Poland
Krakowska Akademia Neurologii Sp. Z o.o
Krakow, Poland
Policlínica Gipuzkoa
San Sebastián, Spain
Hospital Universitario Virgen del Rocío
Seville, Andalusia, Spain
Hospital Universitari Vall d'Hebron
Barcelona, Barcelona, Spain
Hospital Universitari General de Catalunya
Sant Cugat del Vallès, Barcelona, Spain
Hospital Universitario Ramón y Cajal
Madrid, Madrid, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.